Fusion Health Care Pvt. Ltd.
50 signals · 41 added · 9 dropped or cut · 0 intermediate projects
Plants in our filings
- Sy. No. 667, Bhiknoor, Kamareddy, Telangana
Signals
| Filing | Molecule | Signal | Stage | t / year | Source |
|---|---|---|---|---|---|
| Jan 2026 | Abacavir sulfate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Aripiprazole | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Atorvastatin | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Canagliflozin | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Dabigatran etexilate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Dapagliflozin | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Darunavir | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Domperidone | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Empagliflozin | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Favipiravir | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Gabapentin | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Gefitinib | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Ibrutinib | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Irbesartan | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Levetiracetam | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Lopinavir | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Losartan potassium | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Nilotinib hydrochloride hydrate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Olmesartan | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Oseltamivir phosphate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Ritonavir | ↓ CAPACITY CUT | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Sorafenib tosylate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Sunitinib maleate | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Telmisartan | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Valsartan | ↑ CAPACITY UP | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Apixaban | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Glimepiride | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Linagliptin | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Linezolid | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Luliconazole | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Midodrine hydrochloride | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Perampanel | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Praziquantel | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Ranolazine | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Rivaroxaban | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Sitagliptin phosphate monohydrate | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Solifenacin succinate | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Vildagliptin | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Furosemide | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Mirabegron | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Montelukast | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Bilastine | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Ezetimibe | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Torsemide | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Fluoxetine hydrochloride | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Silodosin | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Lisinopril dihydrate | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Enoxaparin sodium | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Vecuronium bromide | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
| Jan 2026 | Meropenem trihydrate | ↑ NEW AT SITE | Public hearing held | — | EIA executive summary, TGPCB |
Need an alternative supplier?
Find current manufacturers for any molecule, with US DMF and CEP status and contacts, in the api-fdf.com database.